DK1596870T4 - Højdosis-ibandronatformulering - Google Patents

Højdosis-ibandronatformulering

Info

Publication number
DK1596870T4
DK1596870T4 DK03813545.5T DK03813545T DK1596870T4 DK 1596870 T4 DK1596870 T4 DK 1596870T4 DK 03813545 T DK03813545 T DK 03813545T DK 1596870 T4 DK1596870 T4 DK 1596870T4
Authority
DK
Denmark
Prior art keywords
ibandronatformulering
high dose
dose
dose ibandronatformulering
Prior art date
Application number
DK03813545.5T
Other languages
English (en)
Other versions
DK1596870T3 (da
Inventor
Hans-G Kaestle
Bernard Meyer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32524013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1596870(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1596870T3 publication Critical patent/DK1596870T3/da
Publication of DK1596870T4 publication Critical patent/DK1596870T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
DK03813545.5T 2002-12-20 2003-08-07 Højdosis-ibandronatformulering DK1596870T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02028745 2002-12-20
PCT/EP2003/008732 WO2004056373A1 (en) 2002-12-20 2003-08-07 High dose ibandronate formulation

Publications (2)

Publication Number Publication Date
DK1596870T3 DK1596870T3 (da) 2007-10-15
DK1596870T4 true DK1596870T4 (da) 2011-06-14

Family

ID=32524013

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07005463.0T DK1790347T3 (da) 2002-12-20 2003-08-07 Højdosis-ibandronat-formulering
DK03813545.5T DK1596870T4 (da) 2002-12-20 2003-08-07 Højdosis-ibandronatformulering

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07005463.0T DK1790347T3 (da) 2002-12-20 2003-08-07 Højdosis-ibandronat-formulering

Country Status (36)

Country Link
US (1) US7923028B2 (da)
EP (2) EP1596870B2 (da)
JP (1) JP4427453B2 (da)
KR (1) KR100694550B1 (da)
CN (1) CN1649598B (da)
AR (2) AR037560A1 (da)
AT (1) ATE369139T1 (da)
AU (1) AU2003250218B2 (da)
BR (1) BR0309691A (da)
CA (1) CA2484494C (da)
CR (1) CR7549A (da)
CY (2) CY1107757T1 (da)
DE (1) DE60315514T3 (da)
DK (2) DK1790347T3 (da)
EC (1) ECSP045418A (da)
EG (1) EG26027A (da)
ES (2) ES2530791T3 (da)
HK (1) HK1080714A1 (da)
HR (1) HRP20041013B1 (da)
IL (2) IL164956A (da)
JO (1) JO2663B1 (da)
MX (1) MXPA04010866A (da)
MY (1) MY143550A (da)
NO (1) NO329690B1 (da)
NZ (2) NZ555514A (da)
PA (1) PA8580601A1 (da)
PE (1) PE20040416A1 (da)
PL (1) PL212072B1 (da)
PT (2) PT1790347E (da)
RU (1) RU2315603C2 (da)
SG (1) SG174628A1 (da)
SI (2) SI1596870T2 (da)
TW (1) TWI342215B (da)
UY (1) UY27942A1 (da)
WO (1) WO2004056373A1 (da)
ZA (1) ZA200408822B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL399493A1 (pl) 2002-05-10 2012-11-05 F. Hoffmann-La Roche Ag Kwasy bisfosfonowe do leczenia i profilaktyki osteoporozy
NZ546349A (en) * 2003-09-29 2010-03-26 Cipla Ltd Pharmaceutical formulation with improved stability
WO2006024024A2 (en) * 2004-08-23 2006-03-02 Teva Pharmaceutical Industries Ltd. Solid and crystalline ibandronate sodium and processes for preparation thereof
KR100908529B1 (ko) * 2005-02-01 2009-07-20 에프. 호프만-라 로슈 아게 이반드로네이트 다형체 에이
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
DE102006012866B4 (de) 2006-03-19 2009-04-09 Uic Gmbh Verfahren zur Abtrennung leichtflüchtiger Komponenten aus einem Stoffgemisch sowie Vorrichtung zur Durchführung dieses Verfahrens
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
WO2008026907A1 (es) * 2006-08-29 2008-03-06 Espinosa Abdala Leopoldo De Je Composición farmacéutica que comprende ibandronato y vitamina d3 para el tratamiento de osteoporosis
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
WO2009018834A1 (en) * 2007-08-06 2009-02-12 Pharmathen S.A. Pharmaceutical composition containing bisphosphonate and method for the preparation thereof
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8399023B2 (en) 2009-07-31 2013-03-19 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102000094B (zh) * 2010-09-27 2013-03-27 天津南开允公医药科技有限公司 一种含有伊班膦酸的药物组合物及制备工艺
KR101244414B1 (ko) * 2010-11-05 2013-03-18 주식회사 바이오파마티스 고함량 이반드론산 함유 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
EP2661262B1 (en) 2011-01-06 2017-11-15 Mahmut Bilgic Improved bisphosphonate formulations
US9854831B2 (en) * 2012-01-20 2018-01-02 Altria Client Services Llc Oral product
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147484A (en) * 1874-02-17 Improvement in shirt-bosom supporters
US139378A (en) * 1873-05-27 Improvement in folding-guides for sewing-machines
US175884A (en) * 1876-04-11 Improvement in galvanic batteries
US97469A (en) * 1869-11-30 Improved compound for disinfecting- and deodorizing
US87550A (en) * 1869-03-09 Improvement in direct-acting steam-engines
US118634A (en) * 1871-08-29 Improvement in attachments of band-cutters and thrashing-machines
US195171A (en) * 1877-09-11 Improvement in jacks for vehicles
DE1248654B (de) 1964-11-11 1967-08-31 Albright & Wilson (Mf g) Limited, Oldbury, Warwickshire (Großbritannien) Verfahren zur Herstellung von Phosphonsäuren und deren Salzen
DE1251759B (de) 1965-03-30 1967-10-12 The Procter S. Gamble Company, Cincinnati, Ohio (V St A) Verfahren zur kontinuierlichen Herstellung von Athan 1 hydroxy - 1 1-diphosphonsaure
US3475486A (en) 1966-09-12 1969-10-28 Monsanto Co Process for preparing phosphonic acids
DE2405254C2 (de) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4134969A (en) 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
US4073838A (en) 1974-08-12 1978-02-14 Boehringer Ingelheim Gmbh Granulating process
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
BE885139A (fr) 1981-03-09 1981-03-09 Vs Chemicko Technologicka Prah Acide 6-amino-1-hydroxyhexylidene-disphosphonique, sels de cet acide et procede de fabrication de ces produits
CH658009A5 (de) 1982-02-12 1986-10-15 Concast Service Union Ag Verfahren und plattenkokille zum kuehlen und stuetzen eines stranges in einer plattenkokille einer stahlstranggiessanlage.
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IT1195993B (it) 1984-01-12 1988-11-03 Gentili Ist Spa Forme farmaceutiche a base di difosfonati
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
DE3512536A1 (de) 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE10199052I1 (de) 1986-11-21 2002-01-10 Novartis Ag Neue substituierte Alkandiphosphonsaeuren
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
CA1339805C (en) 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FR2629716B1 (fr) 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
GB8808138D0 (en) 1988-04-07 1988-05-11 Leo Pharm Prod Ltd Chemical compounds
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4958839A (en) 1988-07-12 1990-09-25 Guzik Technical Enterprises, Inc. Disc clamp employing resilient cone for spreading balls
US4990503A (en) 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives
US5018651A (en) 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
DE3917153A1 (de) 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5356887A (en) 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5203253A (en) * 1990-10-09 1993-04-20 Ore-Ida Foods, Inc. Automatic air cooking system for vending machines
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
TW237386B (da) 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5431920A (en) 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
TW390813B (en) † 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5462932A (en) 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
DE69530308T2 (de) 1994-09-22 2003-10-16 Akzo Nobel Nv Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung
FR2727629A1 (fr) * 1994-12-06 1996-06-07 Sanofi Sa Trousse pour cycle de traitement de l'osteoporose
US20010051616A1 (en) 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
CA2234817A1 (en) † 1995-10-27 1997-05-01 Mandana Asgharnejad Wet granulation formulation of a growth hormone secretagogue
US6123964A (en) * 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
CN1222079A (zh) * 1996-04-20 1999-07-07 曼海姆泊灵格股份公司 含有伊波膦酸盐的口服药物制剂
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US6905701B2 (en) 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
DK0989848T3 (da) 1997-06-11 2005-01-17 Procter & Gamble Filmovertrukken tablet til forbedret sikkerhed i øvre mave-tarm-kanal
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
IL121623A (en) 1997-08-26 2000-06-29 Unipharm Ltd Process for the preparation of solid oral dosage forms comprising alendronic acid
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
AU757104B2 (en) 1998-06-24 2003-01-30 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
IT1303672B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
DE19846687C2 (de) 1998-10-09 2001-07-26 Auer Dorothee Chirurgische Hilfsvorrichtung zur Verwendung beim Ausführen von medizinischen Eingriffen und Verfahren zum Erzeugen eines Bildes im Rahmen von medizinischen Eingriffen
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
DE69927048T2 (de) 1998-12-04 2006-06-08 Roche Diagnostics Gmbh Ibandroinsäure zur förderung der osseointegration der endoprothesen
SE9901272D0 (sv) 1999-04-09 1999-04-09 Astra Ab New improved formulation
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
FR2797185B1 (fr) * 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
US7271187B2 (en) 2000-04-06 2007-09-18 Tim Neuberger Compositions and methods for promoting tissue regeneration
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
JP4722375B2 (ja) 2000-06-20 2011-07-13 ノバルティス アーゲー ビホスホネートの投与法
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
AU2001273125A1 (en) † 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
JP3563070B2 (ja) * 2000-07-17 2004-09-08 山之内製薬株式会社 経口吸収改善医薬組成物
US6638920B2 (en) 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
ATE297740T1 (de) 2001-01-23 2005-07-15 Gador Sa Bisphosphonate-enthaltenden zusammensetzungen zur vorbeugung und/oder heilung von metabolischen knochenkrankheiten, verfahren zu ihren herstellung und benutzung dieser zusammensetzungen
AR034199A1 (es) 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
ATE496624T1 (de) 2001-02-06 2011-02-15 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
JP4354698B2 (ja) 2001-03-01 2009-10-28 エミスフェアー・テクノロジーズ・インク ビスホスホネートデリバリー用組成物
US6692850B2 (en) * 2001-03-07 2004-02-17 Axsun Technologies, Inc. Controlled stress optical coatings for membranes
WO2002091993A2 (en) 2001-05-10 2002-11-21 Merck & Co., Inc. Estrogen receptor modulators
EP1458400A1 (en) 2001-12-13 2004-09-22 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
AU2002360619B2 (en) 2001-12-21 2006-10-05 Allergan Pharmaceuticals International Limited Method for the treatment of bone disorders
US20050070504A1 (en) 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
CA2480814A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
PL399493A1 (pl) † 2002-05-10 2012-11-05 F. Hoffmann-La Roche Ag Kwasy bisfosfonowe do leczenia i profilaktyki osteoporozy

Also Published As

Publication number Publication date
DE60315514T3 (de) 2012-04-26
US7923028B2 (en) 2011-04-12
EP1596870B2 (en) 2011-04-06
ES2291749T5 (es) 2011-07-21
SI1790347T1 (sl) 2015-03-31
CN1649598B (zh) 2011-12-07
NZ536273A (en) 2007-08-31
CY1107757T1 (el) 2013-06-19
MXPA04010866A (es) 2005-01-25
CY1116123T1 (el) 2017-02-08
EP1596870A1 (en) 2005-11-23
ZA200408822B (en) 2006-01-25
EP1790347B1 (en) 2014-12-24
IL200849A0 (en) 2010-05-17
AR037560A1 (es) 2004-11-17
RU2004132186A (ru) 2006-01-27
IL164956A0 (en) 2005-12-18
JP2006511560A (ja) 2006-04-06
CA2484494A1 (en) 2004-07-08
CR7549A (es) 2006-02-07
ES2530791T3 (es) 2015-03-05
NZ555514A (en) 2008-12-24
TW200412978A (en) 2004-08-01
PA8580601A1 (es) 2004-09-16
PT1790347E (pt) 2015-02-05
EP1790347A1 (en) 2007-05-30
SG174628A1 (en) 2011-10-28
EP1596870B1 (en) 2007-08-08
NO20044722L (no) 2004-11-01
BR0309691A (pt) 2005-08-02
HK1080714A1 (en) 2006-05-04
CA2484494C (en) 2009-05-12
EG26027A (en) 2012-12-11
DK1790347T3 (da) 2015-01-19
DE60315514D1 (de) 2007-09-20
DE60315514T2 (de) 2008-04-24
DK1596870T3 (da) 2007-10-15
AU2003250218A1 (en) 2004-07-14
PL212072B1 (pl) 2012-08-31
SI1596870T2 (sl) 2011-07-29
KR20050044762A (ko) 2005-05-12
ES2291749T3 (es) 2008-03-01
ATE369139T1 (de) 2007-08-15
PE20040416A1 (es) 2004-07-12
HRP20041013A2 (en) 2005-06-30
CN1649598A (zh) 2005-08-03
WO2004056373A1 (en) 2004-07-08
JO2663B1 (en) 2012-06-17
PL373655A1 (en) 2005-09-05
RU2315603C2 (ru) 2008-01-27
ECSP045418A (es) 2005-01-03
AU2003250218B2 (en) 2006-10-26
NO329690B1 (no) 2010-11-29
HRP20041013B1 (hr) 2013-10-25
IL164956A (en) 2013-02-28
UY27942A1 (es) 2004-02-27
AR059723A2 (es) 2008-04-23
KR100694550B1 (ko) 2007-03-13
SI1596870T1 (sl) 2007-12-31
JP4427453B2 (ja) 2010-03-10
PT1596870E (pt) 2007-10-15
MY143550A (en) 2011-05-31
TWI342215B (en) 2011-05-21
US20040121007A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
DE60330207D1 (de) le
IS7689A (is) Fjölþátta lyfjaskammtaform
DK3473251T3 (da) Nikotin-cellulose-kombination
DE60323499D1 (de) Tastverhältnisschätzer
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
ATE318817T1 (de) Aza-arylpiperazine
ATE427876T1 (de) Luftkissenboot
DK1596870T4 (da) Højdosis-ibandronatformulering
ATE349458T1 (de) Etonogestrelester
ATA1572002A (de) Managementspleisskassette
ATA4142004A (de) Trägerverbau
ITMI20022179A1 (it) Il manopoliero
ATE469773T1 (de) Zugöse
DK1494939T3 (da) Doseringsanordning
FI20021675A0 (fi) Levityslaite
ATA19152002A (de) Hubkupplung
ATE396192T1 (de) N-sulfonylaminothiazole
DE10244834B8 (de) Suszeptometer
ATA16872002A (de) Zwischenstück
AT5889U3 (de) Brennholzspleisser
DE10211707A8 (de) Segmentstatormaschine
NO20031725L (no) Borefikstur
NO20043433L (no) Fremgangsmate
ATA5582002A (de) Getränkeerhitzer